News
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange
San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018
The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors and fulvestrant, a SERD, in preclinical in-vitro breast cancer models
Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange
San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018
Sigma1 Modulator Induces Degradation of PD-L1
Maher, CM, Thomas, JD, Longen, CG, Oyer, HM, Kim, FJ, et al. Molecular Cancer Research.